```
FILE 'HOME' ENTERED AT 17:52:54 ON 05 MAR 2003

=> index chemistry bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

INDEX 'AGRICOLA, ALUMINIUM, ANABSTR, APOLLIT, AQUIRE, BABS, BIOCOMMERCE,
       BIOTECHNO, CABA, CAOLD, CAPLUS, CBNB, CEABA-VTB, CEN, CERAB, CIN,
       COMPENDEX, CONFSCI, COPPERLIT, CORROSION, ENCOMPLIT, ENCOMPLIT2, FEDRIP,
       GENBANK, INSPEC, INSPHYS, INVESTEXT, IPA, ...'
ENTERED AT 17:53:18 ON 05 MAR 2003

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (growth (w) hormone) (s) (crystal? or crystalization)
           5   FILE AGRICOLA
           2   FILE ANABSTR
           1   FILE APOLLIT
           9   FILE BABS
           2   FILE BIOCOMMERCE
          70   FILE BIOTECHNO
          15   FILE CABA
           8   FILE CAOLD
         118   FILE CAPLUS
           1   FILE CBNB
           2   FILE CEABA-VTB
           2   FILE CEN
           1   FILE CIN
           2   FILE COMPENDEX
  17 FILES SEARCHED...
          13*  FILE FEDRIP
          16   FILE INSPEC
          22   FILE INVESTEXT
  31 FILES SEARCHED...
           2   FILE NTIS
          32   FILE PASCAL
           7   FILE PROMT
           2   FILE RAPRA
         107   FILE SCISEARCH
  44 FILES SEARCHED...
           1   FILE ADISINSIGHT
           1   FILE ADISNEWS
           5   FILE AQUASCI
           3   FILE BIOBUSINESS
         124   FILE BIOSIS
           9   FILE BIOTECHABS
           9   FILE BIOTECHDS
          40   FILE CANCERLIT
          11   FILE DDFU
          28   FILE DGENE
          16   FILE DRUGU
  65 FILES SEARCHED...
         118   FILE EMBASE
          55   FILE ESBIOBASE
           2   FILE FSTA
          20   FILE IFIPAT
          42   FILE LIFESCI
         119   FILE MEDLINE
           3   FILE OCEAN
           1   FILE PHIN
```

```
        20   FILE TOXCENTER
  86 FILES SEARCHED...
       185   FILE USPATFULL
         4   FILE USPAT2
         1   FILE VETU
        25   FILE WPIDS
        25   FILE WPINDEX

  47 FILES HAVE ONE OR MORE ANSWERS,   92 FILES SEARCHED IN STNINDEX

L1   QUE (GROWTH (W) HORMONE) (S) (CRYSTAL? OR CRYSTALIZATION)

=> file hits
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     4.95       5.16

FILE 'USPATFULL' ENTERED AT 17:58:41 ON 05 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 17:58:41 ON 05 MAR 2003

FILE 'CAPLUS' ENTERED AT 17:58:41 ON 05 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'BIOTECHNO' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'LIFESCI' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)


FILE 'CANCERLIT' ENTERED AT 17:58:41 ON 05 MAR 2003

FILE 'PASCAL' ENTERED AT 17:58:41 ON 05 MAR 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'DGENE' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'INVESTEXT' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Thomson Financial Services, Inc. (TFS)
```

FILE 'IFIPAT' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'TOXCENTER' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 ACS

FILE 'INSPEC' ENTERED AT 17:58:41 ON 05 MAR 2003
Compiled and produced by the IEE in association with FIZ KARLSRUHE
COPYRIGHT 2003 (c) INSTITUTION OF ELECTRICAL ENGINEERS (IEE)

FILE 'DRUGU' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CABA' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'FEDRIP' ENTERED AT 17:58:41 ON 05 MAR 2003

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'BABS' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (c) 2003 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'CAOLD' ENTERED AT 17:58:41 ON 05 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PROMT' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'AGRICOLA' ENTERED AT 17:58:41 ON 05 MAR 2003

FILE 'AQUASCI' ENTERED AT 17:58:41 ON 05 MAR 2003
(c) 2003 FAO (on behalf of the ASFA Advisory Board) All rights reserved.

FILE 'USPAT2' ENTERED AT 17:58:41 ON 05 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOBUSINESS' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'OCEAN' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'BIOCOMMERCE' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights
reserved

FILE 'CEABA-VTB' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (c) 2003 DECHEMA eV

FILE 'CEN' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

```
FILE 'COMPENDEX' ENTERED AT 17:58:41 ON 05 MAR 2003
Compendex Compilation and Indexing (C) 2003
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'NTIS' ENTERED AT 17:58:41 ON 05 MAR 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2003)

FILE 'RAPRA' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 RAPRA Technology Ltd.

FILE 'FSTA' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'APOLLIT' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (c) 2003 FIZ Karlsruhe

FILE 'CBNB' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (c) 2003 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 17:58:41 ON 05 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'ADISINSIGHT' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Adis International Ltd. (ADIS)

FILE 'ADISNEWS' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Adis International Ltd. (ADIS)

FILE 'PHIN' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'VETU' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

=> s l1
L2          185 FILE USPATFULL
L3          124 FILE BIOSIS
L4          119 FILE MEDLINE
L5          118 FILE CAPLUS
L6          118 FILE EMBASE
L7          107 FILE SCISEARCH
L8           70 FILE BIOTECHNO
L9           55 FILE ESBIOBASE
L10          42 FILE LIFESCI
L11          40 FILE CANCERLIT
L12          32 FILE PASCAL
L13          28 FILE DGENE
L14          25 FILE WPIDS
L15          22 FILE INVESTEXT
L16          20 FILE IFIPAT
L17          20 FILE TOXCENTER
L18          16 FILE INSPEC
L19          16 FILE DRUGU
L20          15 FILE CABA
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HORMONE) (S) '
L21          13 FILE FEDRIP
L22           9 FILE BABS
L23           9 FILE BIOTECHDS
L24           8 FILE CAOLD
```

```
L25           7 FILE PROMT
L26           5 FILE AGRICOLA
L27           5 FILE AQUASCI
L28           4 FILE USPAT2
L29           3 FILE BIOBUSINESS
L30           3 FILE OCEAN
L31           2 FILE ANABSTR
L32           2 FILE BIOCOMMERCE
L33           2 FILE CEABA-VTB
L34           2 FILE CEN
L35           2 FILE COMPENDEX
L36           2 FILE NTIS
L37           2 FILE RAPRA
L38           2 FILE FSTA
L39           1 FILE APOLLIT
L40           1 FILE CBNB
L41           1 FILE CIN
L42           1 FILE ADISINSIGHT
L43           1 FILE ADISNEWS
L44           1 FILE PHIN
L45           1 FILE VETU

TOTAL FOR ALL FILES
L46        1261 L1

=> s l46 and caion? and (organic (w) solvent?)
L47           0 FILE USPATFULL
L48           0 FILE BIOSIS
L49           0 FILE MEDLINE
L50           0 FILE CAPLUS
L51           0 FILE EMBASE
L52           0 FILE SCISEARCH
L53           0 FILE BIOTECHNO
L54           0 FILE ESBIOBASE
L55           0 FILE LIFESCI
L56           0 FILE CANCERLIT
L57           0 FILE PASCAL
L58           0 FILE DGENE
<------User Break------>

SEARCH ENDED BY USER

=> s l46 and cation? and (organic (w) solvent?)
L59          26 FILE USPATFULL
L60           0 FILE BIOSIS
L61           0 FILE MEDLINE
L62           0 FILE CAPLUS
L63           0 FILE EMBASE
L64           0 FILE SCISEARCH
L65           0 FILE BIOTECHNO
L66           0 FILE ESBIOBASE
L67           0 FILE LIFESCI
L68           0 FILE CANCERLIT
L69           0 FILE PASCAL
L70           0 FILE DGENE
L71           1 FILE WPIDS
L72           0 FILE INVESTEXT
L73           1 FILE IFIPAT
L74           0 FILE TOXCENTER
L75           0 FILE INSPEC
L76           0 FILE DRUGU
L77           0 FILE CABA
L78           0 FILE FEDRIP
L79           0 FILE BABS
L80           0 FILE BIOTECHDS
```

```
L81           0 FILE CAOLD
L82           0 FILE PROMT
L83           0 FILE AGRICOLA
L84           0 FILE AQUASCI
L85           1 FILE USPAT2
L86           0 FILE BIOBUSINESS
L87           0 FILE OCEAN
L88           0 FILE ANABSTR
L89           0 FILE BIOCOMMERCE
L90           0 FILE CEABA-VTB
L91           0 FILE CEN
L92           0 FILE COMPENDEX
L93           0 FILE NTIS
L94           0 FILE RAPRA
L95           0 FILE FSTA
L96           0 FILE APOLLIT
L97           0 FILE CBNB
L98           0 FILE CIN
L99           0 FILE ADISINSIGHT
L100          0 FILE ADISNEWS
L101          0 FILE PHIN
L102          0 FILE VETU

TOTAL FOR ALL FILES
L103         29 L46 AND CATION? AND (ORGANIC (W) SOLVENT?)

=> D l103 1-29 ibib abs

L103 ANSWER 1 OF 29  USPATFULL
ACCESSION NUMBER:        2003:30295  USPATFULL
TITLE:                   Particles with improved solubilization capacity
INVENTOR(S):             Anderson, David, Colonial Heights, VA, UNITED STATES

                              NUMBER       KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2003022242      A1   20030130
APPLICATION INFO.:       US 2002-176112     A1   20020621  (10)

                               NUMBER        DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2001-300476P    20010623 (60)
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    WHITHAM, CURTIS & CHRISTOFFERSON, P.C., 11491 SUNSET
                         HILLS ROAD, SUITE 340, RESTON, VA, 20190
NUMBER OF CLAIMS:        204
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      1 Drawing Page(s)
LINE COUNT:              3885
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB       A particle is disclosed that comprises a first volume of hydrophobe-rich
         material with tunable dissolution and solubilization characteristics and
         a distinct second volume of nanostructured nonlamellar liquid
         crystalline material, said second volume containing said first domain
         and being capable of being in equilibrium with said first volume.
         Preferably, the nanostructured nonlamellar liquid crystalline material
         is capable of being in equilibrium with a polar solvent or a
         water-immiscible solvent or both.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 2 OF 29  USPATFULL
ACCESSION NUMBER:        2002:346976  USPATFULL
TITLE:                   Methods of preparing carbohydrate crosslinked
                         glycoprotein crystals
```

INVENTOR(S): Margolin, Alexey L., Newton, MA, United States
Govardhan, Chandrika P., Lexington, MA, United States
Visuri, Kalevi J., Kirkkonummi, FINLAND
Uotila, Sinikka S., Espoo, FINLAND
PATENT ASSIGNEE(S): Altus Biologics Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6500933	B1	20021231
APPLICATION INFO.:	US 2000-518849		20000303 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1998-US16372, filed on 6 Aug 1998 Continuation-in-part of Ser. No. US 1999-314717, filed on 19 May 1999, now patented, Pat. No. US 6359118 Continuation of Ser. No. US 1997-926279, filed on 5 Sep 1997, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Mohamed, Abdel A.
LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Pierri, Margaret A.
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1964
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the field of carbohydrate crosslinked glycoprotein crystals. Advantageously, such crosslinked glycoprotein crystals display stability to harsh environmental conditions, while maintaining the structural and functional integrity of the glycoprotein backbone. According to one embodiment, this invention relates to methods for concentrating proteins that have been modified by carbohydrates and for releasing their activity at controlled rates. This invention also provides methods for producing carbohydrate crosslinked glycoprotein crystals and methods for using them in pharmaceutical formulations, vaccines, immunotherapeutics, personal care compositions, including cosmetics, veterinary pharmaceutical compositions and vaccines, foods, feeds, diagnostics, cleaning agents, including detergents and decontamination formulations. The physical and chemical characteristics of carbohydrate crosslinked glycoprotein crystals render them particularly useful as sorbents for separations, such as chiral chromatography, or affinity chromatography--which are based on specific interactions between the active binding site of the glycoprotein component of the crystals and the substance or molecule of interest. Such characteristics also render carbohydrate crosslinked glycoprotein crystals useful as catalytic and binding components for the production of biosensing devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 3 OF 29 USPATFULL
ACCESSION NUMBER: 2002:344627 USPATFULL
TITLE: THERAPEUTIC USE OF THE SMR 1 PROTEIN AND ACTIVE DERIVATIVES THEREOF
INVENTOR(S): ROUGEOT, CATHERINE, CHEVREU, FRANCE
ROUGEON, FRANCOIS, POIGNY LA FORET, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198361	A1	20021226
APPLICATION INFO.:	US 1999-367703	A1	19991013 (9)
	WO 1998-EP956		19980219

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT, 1755

JEFFERSON DAVIS HIGHWAY, FOURTH FLOOR, ARLINGTON, VA, 22202
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 2466
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating diseases associated with a mineral ion imbalance in a human or an animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating an hydromineral imbalance in organs and tissues such as kidney, bone, dental enamel, dental ivory, gut matrix, pancreas or glandular gastric mucosa. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecoles as well as with therapeutic methods using the said therapeutic compostions. Finally, the present invention rekates to processes for selecting ligand molecules that posses an agonist or an antagonist biological activity on the target receptor of the QHNPR pentapeptide as well as to be selected ligand molecules themselves.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 4 OF 29 USPATFULL
ACCESSION NUMBER: 2002:290772 USPATFULL
TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods
INVENTOR(S): Cech, Thomas R., Boulder, CO, United States
Lingner, Joachim, Epalinges, SWITZERLAND
Nakamura, Toru, Boulder, CO, United States
Chapman, Karen B., Sausalito, CA, United States
Morin, Gregg B., Palo Alto, CA, United States
Harley, Calvin B., Palo Alto, CA, United States
Andrews, William H., Richmond, CA, United States
PATENT ASSIGNEE(S): University Technology Corporation, Boulder, CO, United States (U.S. corporation)
Geron Corporation, Menlo Park, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6475789	B1	20021105
APPLICATION INFO.:	US 1997-912951		19970814 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-845050, filed on 9 May 1997, now patented, Pat. No. US 5743518 Continuation-in-part of Ser. No. US 1997-851843, filed on 6 May 1997, now patented, Pat. No. US 6093809 Continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997, now abandoned Continuation-in-part of Ser. No. US 1997-844419, filed on 18 Apr 1997, now abandoned Continuation-in-part of Ser. No. US 1996-724643, filed on 1 Oct 1996, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Eyler, Yvonne
ASSISTANT EXAMINER: Andres, Janet L.
LEGAL REPRESENTATIVE: Schiff, J. Michael, Earp, David J., Ausenhus, Scott L.
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 40 Drawing Figure(s); 34 Drawing Page(s)
LINE COUNT: 11405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis, and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 5 OF 29 USPATFULL
ACCESSION NUMBER: 2002:251941 USPATFULL
TITLE: Carbohydrate crosslinked glycoprotein crystals
INVENTOR(S): Margolin, Alexey L., Newton, MA, UNITED STATES
Govardhan, Chandrika Poorna, Lexington, MA, UNITED STATES
Visuri, Kalevi, Kantvik, FINLAND
Uotila, Sinikka, Espoo, FINLAND
PATENT ASSIGNEE(S): Altus Biologics Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002137899	A1	20020926
APPLICATION INFO.:	US 2002-47605	A1	20020114 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-314717, filed on 19 May 1999, GRANTED, Pat. No. US 6359118 Continuation of Ser. No. US 1997-926279, filed on 5 Sep 1997, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
LINE COUNT: 2113
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the field of carbohydrate crosslinked glycoprotein crystals. Advantageously, such crosslinked glycoprotein crystals display stability to harsh environmental conditions, while maintaining the structural and functional integrity of the glycoprotein backbone. According to one embodiment, this invention relates to methods for concentrating proteins that have been modified by carbohydrates and for releasing their activity at controlled rates. This invention also provides methods for producing carbohydrate crosslinked glycoprotein crystals and methods for using them in pharmaceutical formulations, vaccines, immunotherapeutics, personal care compositions, including cosmetics, veterinary pharmaceutical compositions and vaccines, foods, feeds, diagnostics, cleaning agents, including detergents and decontamination formulations. The physical and chemical characteristics of carbohydrate crosslinked glycoprotein crystals render them particularly useful as sorbents for separations, such as chiral chromatography, or affinity chromatography--which are based on specific interactions between the active binding site of the glycoprotein component of the crystals and the substance or molecule of interest. Such characteristics also render carbohydrate crosslinked glycoprotein crystals useful as catalytic and binding components for the production of biosensing devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 6 OF 29 USPATFULL
ACCESSION NUMBER: 2002:251211 USPATFULL
TITLE: CONTROLLED DISSOLUTION CROSSLINKED PROTEIN CRYSTALS
INVENTOR(S): MARGOLIN, ALEXEY L., NEWTON, MA, UNITED STATES
PERSICHETTI, ROSE A., STOW, MA, UNITED STATES
ST. CLAIR, NANCY L., ANN ARBOR, MI, UNITED STATES

KHALAF, NAZER K., Worchester, MA, UNITED STATES
SHENOY, BHAMI C., Woburn, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002137156	A1	20020926
APPLICATION INFO.:	US 1999-459395	A1	19991203 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1998-US7287, filed on 10 Apr 1998, UNKNOWN Continuation-in-part of Ser. No. US 1997-834661, filed on 11 Apr 1997, PATENTED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FISH & NEAVE, MARGARET A PIERRI ESQ, 1251 AVENUE OF THE AMERICAS, NEW YORK, NY, 10020-1104
NUMBER OF CLAIMS: 97
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 3578
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to crosslinked protein crystals characterized by the ability to change from insoluble and stable form to soluble and active form upon a change in the environment of said crystals, said change being selected from the group consisting of change in temperature, change in pH, change in chemical composition, change from concentrate to dilute form, change in oxidation-reduction potential of the solution, change in the incident radiation, change in transition metal concentration, change in flouride concentration, change in free radical concentration, change in metal chelater concentration, change in shear force acting upon the crystals and combinations thereof. According to one embodiment of this invention, such crosslinked protein crystals are capable of releasing their protein activity at a controlled rate. This invention also provides methods for producing such crosslinked protein crystals, methods using them for protein delivery and methods using them in cleaning agents, including detergents, pharmaceutical compositions, vaccines, personal care compositions, including cosmetics, veterinary compositions, foods, feeds, diagnostics and formulations for decontamination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 7 OF 29 USPATFULL
ACCESSION NUMBER: 2002:179201 USPATFULL
TITLE: Intermittent administration of a growth hormone secretagogue
INVENTOR(S): MacLean, David B., Providence, RI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002094992	A1	20020718
APPLICATION INFO.:	US 2001-940165	A1	20010827 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-229077P	20000830 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point Road, Groton, CT, 06340
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 2898
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the intermittent administration of a growth hormone secretagogue to a patient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 8 OF 29 USPATFULL
ACCESSION NUMBER: 2002:85540 USPATFULL
TITLE: STABILIZED PROTEIN CRYSTALS FORMULATIONS CONTAINING THEM AND METHODS OF MAKING THEM
INVENTOR(S): MARGOLIN, ALEXEY L., NEWTON, MA, UNITED STATES
KHALAF, NAZAR K., WORCESTER, MA, UNITED STATES
CLAIR, NANCY L. ST., ANN ARBOR, MI, UNITED STATES
RAKESTRAW, SCOTT L., NEWARK, DE, UNITED STATES
SHENOY, BHAMI C., WOBURN, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002045582	A1	20020418
APPLICATION INFO.:	US 1999-374132	A1	19990810 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1999-US9099, filed on 27 Apr 1999, UNKNOWN Continuation-in-part of Ser. No. US 1998-224475, filed on 31 Dec 1998, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-83148P	19980427 (60)
	US 1997-70274P	19971231 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MARGARET A PIERRI, FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, NEW YORK, NY, 100201104
NUMBER OF CLAIMS: 187
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 24 Drawing Page(s)
LINE COUNT: 4131
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein or nucleic acid crystals, formulations and compositions comprising them. Methods are provided for the crystallization of proteins and nucleic acids and for the preparation of stabilized protein or nucleic acid crystals for use in dry or slurry formulations. The present invention is further directed to encapsulating proteins, glycoproteins, enzymes, antibodies, hormones and peptide crystals or crystal formulations into compositions for biological delivery to humans and animals. According to this invention, protein crystals or crystal formulations are encapsulated within a matrix comprising a polymeric carrier to form a composition. The formulations and compositions enhance preservation of the native biologically active tertiary structure of the proteins and create a reservoir which can slowly release active protein where and when it is needed. Methods are provided preparing stabilized formulations using pharmaceutical ingredients or excipients and optionally encapsulating them in a polymeric carrier to produce compositions and using such protein crystal formulations and compositions for biomedical applications, including delivery of therapeutic proteins and vaccines. Additional uses for the protein crystal formulations and compositions of this invention involve protein delivery in human food, agricultural feeds, veterinary compositions, diagnostics, cosmetics and personal care compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 9 OF 29 USPATFULL
ACCESSION NUMBER: 2002:32187 USPATFULL
TITLE: THERAPEUTIC USE OF THE SMR1 PROTEIN, THE SMR1 MATURATION PRODUCTS, SPECIFICALLY THE QHNPR PENTAPEPTIDE AS WELL AS ITS BIOLOGICALLY ACTIVE

DERIVATIVES
INVENTOR(S): ROUGEOT, CATHERINE, CHEVREUSE, FRANCE
ROUGEON, FRANCOIS, POIGUY LA FORET, FRANCE

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002019008	A1	20020214	
APPLICATION INFO.:	US 1997-801405	A1	19970220	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 2135
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR1 (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating diseases associated with a mineral ion imbalance in a human or an animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating an hydro-mineral imbalance in organs and tissues such as kidney, bone, dental enamel, dental ivory, gut matrix, pancreas or glandular gastric mucosa. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions. Finally, the present invention relates to processes for selecting ligand molecules that possess an agonist or an antagonist biological activity on the target receptor of the QHNPR pentapeptide as well as to the selected ligand molecules themselves.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 10 OF 29 USPATFULL
ACCESSION NUMBER: 2001:152708 USPATFULL
TITLE: Production of high titers of gibberellins, GA4 and GA7, by Gibberella fujikuroi strain LTB-1027
INVENTOR(S): Gallazzo, Jorge L., 1145 W. Knickerbocker Dr., Sunnyvale, CA, United States 94087
Lee, May D., 1335 Carbo Ct., Los Altos, CA, United States 94024

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6287800	B1	20010911	
APPLICATION INFO.:	US 2000-645073		20000823	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-151770P	19990831	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Weber, Jon P.
ASSISTANT EXAMINER: Guttman, Harry J.
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 519
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A new method of producing a mixture of gibberellins which is predominantly GA.sub.4 and GA.sub.7 but also contains GA.sub.3 has the steps of providing a seed of Gibberella fujikuroi Strain LTB-1027 or mutants derived therefrom, inoculating the seed into a culture medium

rich in carbohydrate and relatively low in nitrogen, incubating the culture for at least four days, separating the Gibberella fujikuroi Strain LTB-1027 from the culture broth, and extracting the gibberellins to produce a gibberellin mixture which is at least 50% GA.sub.4 and GA.sub.7. The method produces a gibberellin mixture in which the combined titer of GA.sub.4 and GA.sub.7 exceeds 800 mg/liter. The production method also produces a gibberellin mixture with approximately equal titers of gibberellins GA.sub.4 and GA.sub.7. A variation of the method produces a gibberellin mixture which contains over 40% GA.sub.4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 11 OF 29 USPATFULL
ACCESSION NUMBER: 2001:114668 USPATFULL
TITLE: CARBOHYDRATE CROSSLINKED GLYCOPROTEIN CRYSTALS
INVENTOR(S): MARGOLIN, ALEXEY L., NEWTON, MA, United States
GOVARDHAN, CHANDRIKA POORNA, LEXINGTON, MA, United States
VISURI, KALEVI, KANTVIK, Finland

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001008934	A1	20010719
	US 6359118	B2	20020319
APPLICATION INFO.:	US 1999-314717	A1	19990519 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-926279, filed on 5 Sep 1997, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MARGARET A PIERRI, FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, NEW YORK, NY, 10020
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
LINE COUNT: 2109
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the field of carbohydrate crosslinked glycoprotein crystals. Advantageously, such crosslinked glycoprotein crystals display stability to harsh environmental conditions, while maintaining the structural and functional integrity of the glycoprotein backbone. According to one embodiment, this invention relates to methods for concentrating proteins that have been modified by carbohydrates and for releasing their activity at controlled rates. This invention also provides methods for producing carbohydrate crosslinked glycoprotein crystals and methods for using them in pharmaceutical formulations, vaccines, immunotherapeutics, personal care compositions, including cosmetics, veterinary pharmaceutical compositions and vaccines, foods, feeds, diagnostics, cleaning agents, including detergents and decontamination formulations. The physical and chemical characteristics of carbohydrate crosslinked glycoprotein crystals render them particularly useful as sorbents for separations, such as chiral chromatography, or affinity chromatography--which are based on specific interactions between the active binding site of the glycoprotein component of the crystals and the substance or molecule of interest. Such characteristics also render carbohydrate crosslinked glycoprotein crystals useful as catalytic and binding components for the production of biosensing devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 12 OF 29 USPATFULL
ACCESSION NUMBER: 2001:59977 USPATFULL
TITLE: Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
INVENTOR(S): Shalaby, Shalaby Wahba, Anderson, SC, United States
Jackson, Steven A., Holliston, MA, United States

Moreau, Jacques-Pierre, Upton, MA, United States
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques, SAS, Paris, France (non-U.S. corporation)
Poly-Med Incorporated, Anderson, SC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6221958	B1	20010424
APPLICATION INFO.:	US 1999-237405		19990126 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-867308, filed on 2 Jun 1997, now patented, Pat. No. US 5863985, issued on 26 Jan 1999 Continuation of Ser. No. US 464735 Continuation of Ser. No. WO 1994-US148, filed on 5 Jan 1994, now patented, Pat. No. WO 5672659, issued on 30 Sep 1997

	NUMBER	DATE
PRIORITY INFORMATION:	IE 1993-930005	19930106

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Conway, John D., Morrill, Brian R.Fish & Richardson
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1348
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a sustained release pharmaceutical composition. The composition includes a polyester containing a free COOH group ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein at least 50% by weight of the polypeptide present in the composition is ionically conjugated to the polyester.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 13 OF 29 USPATFULL
ACCESSION NUMBER: 2001:47617 USPATFULL
TITLE: Uses of oil bodies
INVENTOR(S): Deckers, Harm M, Calgary, Canada
van Rooijen, Gijs, Calgary, Canada
Boothe, Joseph, Calgary, Canada
Goll, Janis, Calgary, Canada
Mahmoud, Soheil, Calgary, Canada
Moloney, Maurice M., Calgary, Canada
PATENT ASSIGNEE(S): Sembiosys Genetics Inc., Calgary, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6210742	B1	20010403
APPLICATION INFO.:	US 2000-610855		20000705 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-84777, filed on 27 May 1998, now patented, Pat. No. US 6146645

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-47753P	19970527 (60)
	US 1997-47779P	19970528 (60)
	US 1998-75863P	19980225 (60)
	US 1998-75864P	19980225 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Dodson, Shelley A.
ASSISTANT EXAMINER: Lamm, Marina
LEGAL REPRESENTATIVE: Bereskin & Parr, Gravelle, Micheline
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1266
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in various domestic and industrial compositions. The emulsions are especially suited for the preparation of food products, personal care products, pharmaceutical products and industrial products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 14 OF 29 USPATFULL
ACCESSION NUMBER: 2001:18010 USPATFULL
TITLE: Oil body based personal care products
INVENTOR(S): Deckers, Harm M., Calgary, Canada
van Rooijen, Gijs, Calgary, Canada
Boothe, Joseph, Calgary, Canada
Goll, Janis, Calgary, Canada
Moloney, Maurice M., Calgary, Canada
PATENT ASSIGNEE(S): Sembiosys Genetics Inc., Calgary, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6183762	B1	20010206
APPLICATION INFO.:	US 1999-448600		19991124 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-84777, filed on 27 May 1998

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-47753P	19970527 (60)
	US 1997-47779P	19970528 (60)
	US 1998-75863P	19980225 (60)
	US 1998-75864P	19980225 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dodson, Shelley A.
ASSISTANT EXAMINER: Lamm, Marina
LEGAL REPRESENTATIVE: Bereskin & Parr
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1774
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in various domestic and industrial compositions. The emulsions are especially suited for the preparation of food products, personal care products, pharmaceutical products and industrial products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 15 OF 29 USPATFULL
ACCESSION NUMBER: 2000:174804 USPATFULL
TITLE: Telomerase catalytic subunit
INVENTOR(S): Cech, Thomas R., Boulder, CO, United States

Lingner, Joachim, Boulder, CO, United States
PATENT ASSIGNEE(S): University Technology Corporation, Boulder, CO, United States (U.S. corporation)
Geron Corporation, Menlo Park, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6166178		20001226
APPLICATION INFO.:	US 1997-974549		19971119 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-915503, filed on 14 Aug 1997, now abandoned And a continuation-in-part of Ser. No. US 1997-912951, filed on 14 Aug 1997 And a continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug 1997 which is a continuation-in-part of Ser. No. US 1997-854050, filed on 9 May 1997 which is a continuation-in-part of Ser. No. US 1997-851843, filed on 6 May 1997 which is a continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997 which is a continuation-in-part of Ser. No. US 1997-844419, filed on 18 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-724643, filed on 1 Oct 1996

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1997-US17618	19971001
	WO 1997-US17885	19971001

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Eyler, Yvonne
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 128 Drawing Figure(s); 103 Drawing Page(s)
LINE COUNT: 23874
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods related to telomerase reverse transcriptase, the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 16 OF 29 USPATFULL
ACCESSION NUMBER: 2000:153280 USPATFULL
TITLE: Uses of oil bodies
INVENTOR(S): Deckers, Harm M, Calgary, Canada
van Rooijen, Gijs, Calgary, Canada
Boothe, Joseph, Calgary, Canada
Goll, Janis, Calgary, Canada
Mahmoud, Soheil, Calgary, Canada
Moloney, Maurice M., Calgary, Canada
PATENT ASSIGNEE(S): Sembiosys Genetics Inc., Calgary, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6146645		20001114
APPLICATION INFO.:	US 1998-84777		19980527 (9)

	NUMBER	DATE

PRIORITY INFORMATION:	US 1997-47753P	19970527 (60)
	US 1997-47779P	19970528 (60)
	US 1998-75863P	19980225 (60)
	US 1998-75864P	19980225 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dodson, Shelley A.
ASSISTANT EXAMINER: Lamm, Marina
LEGAL REPRESENTATIVE: Bereskin & Parr
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in various domestic and industrial compositions. The emulsions are especially suited for the preparation of food products, personal care products, pharmaceutical products and industrial products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 17 OF 29 USPATFULL
ACCESSION NUMBER: 2000:121627 USPATFULL
TITLE: **Growth hormone crystals** and a process for production of these GH-**crystals**
INVENTOR(S): Junker, Flemming, Humleb.ae butted.k, Denmark
Theisen, Claus Friis, K.o slashed.benhavn, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117984		20000912
APPLICATION INFO.:	US 1998-63749		19980421 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-350758, filed on 7 Dec 1994, now patented, Pat. No. US 5780599 which is a continuation of Ser. No. US 1994-222515, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 961932

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1990-1687	19900713

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Moezie, F. T.
LEGAL REPRESENTATIVE: Zelson, Steve T., Gregg, Valeta
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 392
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Divalent **cation** crystals of human growth factor (hGH) or derivatives thereof, and pharmaceutical preparations comprising divalent **cation** crystals of hGH. In specific embodiments, the divalent **cation** is Zn++ and the molar ration Zn++ and hGH is about 0.2 to about 10.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 18 OF 29 USPATFULL

ACCESSION NUMBER: 1999:155679 USPATFULL
TITLE: Human mutant tissue factor compositions useful as tissue factor antagonists
INVENTOR(S): Ruf, Wolfram, San Diego, CA, United States
Edgington, Thomas S., La Jolla, CA, United States
PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994296		19991130
APPLICATION INFO.:	US 1998-35241		19980305 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 416872
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Schnizer, Holly
LEGAL REPRESENTATIVE: Fitting, Thomas, Homes, Emily
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes a mutant human tissue factor protein which binds functional Factor VII/VIIa but is substantially free of functional procoagulant cofactor activity, and compositions containing the mutant protein. Also disclosed are methods for using the mutant human tissue factor proteins, and recombinant DNA vectors for expressing the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 19 OF 29 USPATFULL
ACCESSION NUMBER: 1999:12993 USPATFULL
TITLE: Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
INVENTOR(S): Shalaby, Shalaby W., Pendleton, SC, United States
Jackson, Steven A., Holliston, MA, United States
Moreau, Jacques-Pierre, Upton, MA, United States
PATENT ASSIGNEE(S): Kinerton Limited, Dublin, Ireland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5863985		19990126
APPLICATION INFO.:	US 1997-867308		19970602 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-464735, filed on 29 Jun 1995, now patented, Pat. No. US 5672659
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Conway, John D.Fish & Richardson
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 959
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed is a sustained release pharmaceutical composition. The composition includes a polyester containing a free COOH group ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein at least 50% by weight of the polypeptide present in the composition is ionically conjugated to the polyester.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 20 OF 29 USPATFULL
ACCESSION NUMBER: 1998:157309 USPATFULL
TITLE: Pharmaceutical formulation
INVENTOR(S): S.o slashed.rensen, Hans Holmegaard, Virum, Denmark
Skriver, Lars, Ved.ae butted.k, Denmark
Hoelgaard, Annie Rassing, Holte, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849704		19981215
APPLICATION INFO.:	US 1995-458386		19950602 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-12817, filed on 3 Feb 1993 which is a continuation-in-part of Ser. No. US 1992-827200, filed on 28 Jan 1992

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1991-2046	19911220
	DK 1992-1364	19921110

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schain, Howard E.
ASSISTANT EXAMINER: Touzeau, Lynn
LEGAL REPRESENTATIVE: Zelson, Steve T., Argis, Cheryl H.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1071
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A pharmaceutical preparation comprising a **growth hormone** and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. **Crystallization** of **growth hormone** in the presence of histidine or a derivative thereof gives rise to a higher yield of **crystals** having a higher purity than known methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 21 OF 29 USPATFULL
ACCESSION NUMBER: 1998:157305 USPATFULL
TITLE: Pharmaceutical formulation
INVENTOR(S): S.o slashed.rensen, Hans Holmegaard, Virum, Denmark
Skriver, Lars, Ved.ae butted.k, Denmark
Hoelgaard, Annie Rassing, Holte, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849700		19981215
APPLICATION INFO.:	US 1995-458385		19950602 (8)

DISCLAIMER DATE: 20181215
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-12817, filed on 3 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-827200, filed on 28 Jan 1992, now abandoned

	NUMBER	DATE

PRIORITY INFORMATION:	DK 1991-2046	19911220
	DK 1992-1364	19921110

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Touzeau, P. Lynn
LEGAL REPRESENTATIVE: Zelson, Esq., Steve T., Agris, Esq., Cheryl H.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1020
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical preparation comprising a **growth hormone** and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. **Crystallization** of **growth hormone** in the presence of histidine or a derivative thereof gives rise to a higher yield of **crystals** having a higher purity than known methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 22 OF 29 USPATFULL
ACCESSION NUMBER: 1998:85943 USPATFULL
TITLE: Methods for treating cancer and other cell proliferative diseases
INVENTOR(S): Schlessinger, Joseph, New York, NY, United States
Lax, Irit, Fair Lawn, NJ, United States
Ladbury, John E., New York, NY, United States
Tang, Peng Cho, Moraga, CA, United States
PATENT ASSIGNEE(S): Sugen, Inc., Redwood City, CA, United States (U.S. corporation)
New York University, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5783568		19980721	
APPLICATION INFO.:	US 1994-258307		19940610	(8)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fonda, Kathleen K.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 1440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treating in a mammal certain cancers, other cell proliferative diseases, and/or angiogenesis by using a salt or complex of a sulfated saccharide. The invention also relates to the use of mutant heparin binding growth factors that bind to the growth factor receptor, but not to heparin. The invention also provides pharmaceutical compositions for such methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 23 OF 29 USPATFULL
ACCESSION NUMBER: 1998:82875 USPATFULL
TITLE: **Growth hormone crystals** and a process for production of **growth**

hormone crystals

INVENTOR(S): Junker, Flemming, Humleb.ae butted.k, Denmark
Theisen, Claus Friss, K.o slashed.benhavn, Denmark

PATENT ASSIGNEE(S): Novo Nordisk A/S, BAgsvaerd, Denmark (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5780599		19980714	
APPLICATION INFO.:	US 1994-350758		19941207	(8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-222515, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 1993-961932, filed on 13 Jan 1993, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1990-1687	19900713

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Sayala, Chhaya D.
LEGAL REPRESENTATIVE: Zelson, Esq., Steve T., Gregg, Esq., Valeta
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of producing chemically stable and biologically active **growth hormone crystals** and processes for production of pharmaceutical preparations containing these **growth hormone crystals**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 24 OF 29 USPATFULL

ACCESSION NUMBER: 1998:34044 USPATFULL
TITLE: Process for manufacturing **crystals** of **growth hormone** and **crystals** thereby obtained
INVENTOR(S): Florin-Robertsson, Ebba, Stockholm, Sweden
Hokby, Elvy, Enskede, Sweden
Lundin, Ronny, Ekero, Sweden
Thome, Sirkka, Stockholm, Sweden
Westin-Sjodahl, Gertrud, Sodertalje, Sweden
PATENT ASSIGNEE(S): Pharmacia & Upjohn Aktiebolag, Stockholm, Sweden (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5734026		19980331	
	WO 9410192		19940511	
APPLICATION INFO.:	US 1995-424450		19950524	(8)
	WO 1993-SE885		19931027	
			19950524	PCT 371 date
			19950524	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1992-3175	19921028
	SE 1993-2278	19930702
	SE 1993-885	19931027

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ulm, John
ASSISTANT EXAMINER: Sacud, Christine
LEGAL REPRESENTATIVE: Pollock, Vande Sande & Priddy

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 624
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A process for manufacturing **crystals** of **growth hormone** (GH) comprising the steps of:

i) mixing GH with an aqueous solution comprising a buffer and a chemical compound with the general formula (1):

Ar--[--CR.sub.1 R.sub.2 --]n--[--C R.sub.3 R.sub.4 --]m--C R.sub.5 R.sub.6 --OH (1)

in which Ar is phenyl, alkyl-substituted phenyl, naphthyl, or alkyl-substituted naphthyl, R.sub.1 to R.sub.6 is H, OH or alkyl and n and m is 0 or 1;

ii) incubating; and

iii) isolating the crystals is provided. The crystals are in the form of needles, trigonal forms, cubes or parallelepipeds with a length of at least 20 microns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 25 OF 29 USPATFULL
ACCESSION NUMBER: 1998:25203 USPATFULL
TITLE: Human mutant tissue factor compositions useful as tissue factor antagonists
INVENTOR(S): Ruf, Wolfram, San Diego, CA, United States
Edgington, Thomas S., La Jolla, CA, United States
PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5726147		19980310	
	WO 9428017		19941208	
APPLICATION INFO.:	US 1995-416872		19950418	(8)
	WO 1994-US6197		19940601	
			19950418	PCT 371 date
			19950418	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-70154, filed on 1 Jun 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fitzgerald, David L.
ASSISTANT EXAMINER: Kemmerer, Elizabeth C.
LEGAL REPRESENTATIVE: Fitting, Thomas, Holmes, Emily
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2370
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes a mutant human tissue factor protein which binds functional Factor VII/VIIa but is substantially free of functional procoagulant cofactor activity, and compositions containing the mutant protein. Also disclosed are methods for using the mutant human tissue factor proteins, and recombinant DNA vectors for expressing the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 26 OF 29 USPATFULL

ACCESSION NUMBER: 97:89035 USPATFULL
TITLE: Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
INVENTOR(S): Shalaby, Shalaby W., Pendleton, SC, United States
Jackson, Steven A., Holliston, MA, United States
Moreau, Jacques-Pierre, Upton, MA, United States
PATENT ASSIGNEE(S): Kinerton Limited, Ireland (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5672659		19970930	
	WO 9415587		19940721	
APPLICATION INFO.:	US 1995-464735		19950629	(8)
	WO 1994-US148		19940105	
			19950629	PCT 371 date
			19950629	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	IE 1993-930005	19930106

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Nutter, Nathan M.
LEGAL REPRESENTATIVE: Fish & Richardson P.C., McGowan, William E.
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 985
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A composition including a polyester containing one or more free COOH groups ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein the polyester contains a member selected from the group of L-lactic acid, D-lactic acid, DL-lactic acid, .epsilon.-caprolactone, p-dioxanone, .epsilon.-caprolic acid, alkylene oxalate, cycloalkylene oxalate, alkylene succinate, .beta.-hydroxybutyrate, substituted or unsubstituted trimethylene carbonate, 1,5-dioxopan-2-one, 1,4-dioxepan-2-one, glycolide, glycolic acid, L-lactide, D-lactide, DL-lactide, meso-lactide, and any optically active isomers, racemates or copolymers thereof, and at least 50%, by weight, of the polypeptide present in the composition is ionically conjugated to said polyester.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 27 OF 29 WPIDS (C) 2003 THOMSON DERWENT
ACCESSION NUMBER: 1992-056826 [07] WPIDS
DOC. NO. CPI: C1992-025665
TITLE: **Cationic crystals** of (pref. human) **growth hormone** - produced by adding inorganic or organic **cations** to **growth hormone** soln. at pH 5-8, growing and isolating **crystals**.
DERWENT CLASS: B04
INVENTOR(S): JUNKER, F; THEISEN, C F; THEISEN, C
PATENT ASSIGNEE(S): (NOVO) NOVO-NORDISK AS; (NOVO) NOVO NORDISK AS
COUNTRY COUNT: 39
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9200998	A	19920123	(199207)*		
RW: AT BE CH DE DK ES FR GB GR IT LU NL SE					
W: AU BG BR CA CS FI HU JP KP KR LK MC MG MW NO PL RO SD SU US					
ZA 9105446	A	19920325	(199218)		18
AU 9182846	A	19920204	(199220)		

PT 98297	A	19920529 (199227)			
EP 540582	A1	19930512 (199319)	EN	18	
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
NZ 238904	A	19930428 (199320)			
JP 05507497	W	19931028 (199348)		7	
HU 64086	T	19931129 (199401)			
EP 540582	B1	19940831 (199433)	EN	15	
R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE					
DE 69103755	E	19941006 (199439)			
ES 2060399	T3	19941116 (199501)			
HU 210323	B	19950328 (199518)			
AU 666465	B	19960215 (199614)			
IE 67054	B	19960221 (199617)			
JP 2524446	B2	19960814 (199637)		6	
US 5780599	A	19980714 (199835)			
RU 2108341	C1	19980410 (199846)			
CA 2086087	C	19990914 (200004)	EN		
US 6117984	A	20000912 (200046)			

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
ZA 9105446	A		ZA 1991-5446	19910712
AU 9182846	A		AU 1991-82846	19910712
			WO 1991-DK203	19910712
PT 98297	A		PT 1991-98297	19910711
EP 540582	A1		EP 1991-913240	19910712
			WO 1991-DK203	19910712
NZ 238904	A		NZ 1991-238904	19910710
JP 05507497	W		JP 1991-512511	19910712
			WO 1991-DK203	19910712
HU 64086	T		WO 1991-DK203	19910712
			HU 1993-67	19910712
EP 540582	B1		EP 1991-913240	19910712
			WO 1991-DK203	19910712
DE 69103755	E		DE 1991-603755	19910712
			EP 1991-913240	19910712
			WO 1991-DK203	19910712
ES 2060399	T3		EP 1991-913240	19910712
HU 210323	B		WO 1991-DK203	19910712
			HU 1993-67	19910712
AU 666465	B		AU 1991-82846	19910712
IE 67054	B		IE 1991-2444	19910712
JP 2524446	B2		JP 1991-512511	19910712
			WO 1991-DK203	19910712
US 5780599	A	Cont of	WO 1991-DK203	19910712
		Cont of	US 1993-961932	19930113
		Cont of	US 1994-222515	19940401
			US 1994-350758	19941207
RU 2108341	C1		WO 1991-DK203	19910712
			RU 1993-5051	19910712
CA 2086087	C		CA 1991-2086087	19910712
			WO 1991-DK203	19910712
US 6117984	A	Cont of	WO 1991-DK203	19910712
		Cont of	US 1993-961932	19930113
		Cont of	US 1994-222515	19940401
		Cont of	US 1994-350758	19941207
			US 1998-63749	19980421

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9182846	A	Based on	WO 9200998

EP 540582	A1	Based on	WO 9200998
JP 05507497	W	Based on	WO 9200998
HU 64086	T	Based on	WO 9200998
EP 540582	B1	Based on	WO 9200998
DE 69103755	E	Based on	EP 540582
		Based on	WO 9200998
ES 2060399	T3	Based on	EP 540582
HU 210323	B	Previous Publ.	HU 64086
		Based on	WO 9200998
AU 666465	B	Previous Publ.	AU 9182846
		Based on	WO 9200998
JP 2524446	B2	Previous Publ.	JP 05507497
		Based on	WO 9200998
CA 2086087	C	Based on	WO 9200998
US 6117984	A	Cont of	US 5780599

PRIORITY APPLN. INFO: DK 1990-1687 19900713

AN 1992-056826 [07] WPIDS

AB WO 9200998 A UPAB: 19931006

Prodn. of **cation crystals** of **growth hormone** (GH) or its derivs. comprises: (a) adding inorganic or organic **cations** to a soln. of GH at pH 5-8; (b) growing **crystals** at a temp. of 0-30 deg C; and (c) isolating the **cation crystals** by known means. Also claimed are **cation crystals** of GH or its derivs..

The pH is 5.0-7.5, pref.5.0-6.8, or 5.8-6.5, pref. 6.0-6.5. The **organic solvent** is selected from short-chained aliphatic, cyclic or aromatic alcohols or ketones pref. ethanol or acetone, or methanol or 2-propanol, and is added at 0.1-50% v/v, pref. 0.1-30%, esp. 6-12%. The **cation** is divalent, pref. Zn(2+), and is added in a concn. below the limit for unspecific pptn. of amorphous material i.e. 0.5-10 molZn(2+)/mol. GH, pref. 1.1-2.2, esp. 1.2-2.0. The temp. is pref. 4-25 deg C. The molar ratio of Zn(2+):GH is 0.2:10, pref. 0.5:5, pref. 0.5:2.0.

USE/ADVANTAGE - The process is used as a purificn. and/or isolation step in the mfr. of GH used in pharmaceutical prepns. GHs derived from humans, bovines, porcines, ovines, salmon, trout or tuna may be purified, pref. humans. The process is fast, efficient and downstream, and as the crystals are highly stable they are produced ready to use without need for reconstitution.

0/1

ABEQ EP 540582 A UPAB: 19931113

Prodn. of **cation crystals** of **growth hormone** (GH) or its derivs. comprises: (a) adding (in)organic **cations** to a soln. of GH at pH 5-8; (b) growing **crystals** at a temp. of 0-30 deg.C; and (c) isolating the **cation crystals** by known means.

The pH is 5.0-7.5, pref. 5.0-6.8 or 5.8-6.5, pref. 6.0-6.5. **Organic solvent** is short-chained aliphatic, cyclic or aromatic alcohols or ketones pref. ethanol or acetone, or methanol or 2-propanol, and is added at 0.1-50% v/v, pref. 0.1-30% esp. 6-12%. **Cation** is divalent, pref. Zn(2+), and is added in a concn. below the limit for unspecific pptn. of amorphous material i.e. 0.5-10 mol. Zn(2+)/mol. GH, pref. 1.1-2.2, esp. 1.2-2.0. Temp. is pref. 4-25 deg.C.. Molar ratio of Zn(2+): GH is 0.2:10, pref. 0.5:5, pref. 0.5:2.0.

USE/ADVANTAGE - As a purificn. and/or isolation step in the mfr. of GH used in pharmaceutical prepns. GHs derived from humans, bovines, porcines, ovines, salmon, trout or tuna may be purified, pref. humans. Process is fast, efficient and downstream, and as the crystals are highly stable they are produced ready to use without need for reconstitution.

ABEQ JP 05507497 W UPAB: 19940120

Prodn. of **cation crystals** of **growth hormone** (GH) or its derivs. comprises: (a) adding inorganic or organic **cations** to a soln. of GH at pH 5-8; (b) growing **crystals** at a temp. of 0-30 deg.C; and (c) isolating the

cation crystals by known means. Also claimed are **cation crystals** of GH or its derivs..

The pH is 5.0-7.5 pref. 5.0-6.8, or 5.8-6.5, pref. 6.0-6.5. The **organic solvent** is selected from short-chained aliphatic, cyclic or aromatic alcohols or ketones pref. ethanol or acetone, or methanol or 2-propanol, and is added at 0.1-50% v/v, pref. 0.1-30%, esp. 0.5-10 molZn(2+)/mol. GH, pref. 1.1-2.2, esp. 1.2-2.0. The temp. is pref. 4-25 deg.C. The molar ratio of Zn(2+):GH is 0.2:10, pref. 0.5:5, pref. 0.5:2.0.

USE/ADVANTAGE - The process is used as a purificn. and/or isolation step in the mfr. of GH used in pharmaceutical prepns. GHs derived from humans, bovines, porcines, ovines, salmon, trout or tuna may be purified, pref. humans. The process is fast, efficient and downstream, and as the crystals are highly stable they are produced ready to use without need for reconstitution.

ABEQ EP 540582 B UPAB: 19941010

A process for production of **cation** crystals of GH or of GH derivatives, comprising the following steps: a) to a solution of GH or derivatives thereof is added **cations** of inorganic or organic nature and an **organic solvent** or a mixture of **organic solvents** at a pH between 5.0 and 6.8; b) growing of crystals at a temperature from about 0 to about 30 deg.C;, and c) isolation of the **cation** crystals by known means.

Dwg.0/1

L103 ANSWER 28 OF 29 IFIPAT COPYRIGHT 2003 IFI

AN	3010123 IFIPAT;IFIUDB;IFICDB
TITLE:	**GROWTH HORMONE CRYSTALS** AND A PROCESS FOR PRODUCTION OF **GROWTH HORMONE CRYSTALS**; ADDING **ORGANIC SOLVENT** MIXTURE CONTAINING DIVALENT METAL **CATION** TO SOLUTION OF **GROWTH HORMONE** TO PRECIPITATE STORAGE STABLE **CRYSTALS** AT TEMPERATURE BETWEEN 0 AND 30 DEGREES CELCIUS AND AT PH 5.8-6.5
INVENTOR(S):	Junker, Flemming, Humleb ae k, DK Theisen, Claus Friss, Kobenhavn, DK
PATENT ASSIGNEE(S):	Novo Nordisk A/S, BAgsvaerd, DK
PRIMARY EXAMINER:	Sayala, Chhaya D
AGENT:	Gregg, Esq., Valeta Zelson, Esq., Steve T.

	NUMBER	PK	DATE
PATENT INFORMATION:	US 5780599		19980714
	(CITED IN 001 LATER PATENTS)		
APPLICATION INFORMATION:	US 1994-350758		19941207
EXPIRATION DATE:	14 Jul 2015		

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
CONTINUATION OF:	US 1993-961932	19930113	ABANDONED
CONTINUATION OF:	US 1994-222515	19940401	ABANDONED

	NUMBER	DATE
PRIORITY APPLN. INFO.:	DK 1990-1687	19900713
FAMILY INFORMATION:	US 5780599	19980714

DOCUMENT TYPE:	UTILITY
FILE SEGMENT:	CHEMICAL GRANTED
NUMBER OF CLAIMS:	23
GRAPHICS INFORMATION:	1 Drawing Sheet(s), 1 Figure(s).

AB A method of producing chemically stable and biologically active

growth hormone crystals and processes for production of pharmaceutical preparations containing these **growth hormone crystals**.
CLMN 23
GI 1 Drawing Sheet(s), 1 Figure(s).

L103 ANSWER 29 OF 29 USPAT2
ACCESSION NUMBER: 2001:114668 USPAT2
TITLE: Carbohydrate crosslinked glycoprotein crystals
INVENTOR(S): Margolin, Alexey L., Newton, MA, United States
Govardhan, Chandrika Poorna, Lexington, MA, United States
Visuri, Kalevi, Kantvik, FINLAND
Uotila, Sinikka, Espoo, FINLAND
PATENT ASSIGNEE(S): Altus Biologies, Inc., Cambridge, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6359118	B2	20020319
APPLICATION INFO.:	US 1999-314717		19990519 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-926279, filed on 5 Sep 1997, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Low, Christopher S. F.
ASSISTANT EXAMINER: Mohamed, Abdel A.
LEGAL REPRESENTATIVE: Fish & Neave, Haley, Jr., James F., Pierri, Margaret A.
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1888
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the field of carbohydrate crosslinked glycoprotein crystals. Advantageously, such crosslinked glycoprotein crystals display stability to harsh environmental conditions, while maintaining the structural and functional integrity of the glycoprotein backbone. According to one embodiment, this invention relates to methods for concentrating proteins that have been modified by carbohydrates and for releasing their activity at controlled rates. This invention also provides methods for producing carbohydrate crosslinked glycoprotein crystals and methods for using them in pharmaceutical formulations, vaccines, immunotherapeutics, personal care compositions, including cosmetics, veterinary pharmaceutical compositions and vaccines, foods, feeds, diagnostics, cleaning agents, including detergents and decontamination formulations. The physical and chemical characteristics of carbohydrate crosslinked glycoprotein crystals render them particularly useful as sorbents for separations, such as chiral chromatography, or affinity chromatography--which are based on specific interactions between the active binding site of the glycoprotein component of the crystals and the substance or molecule of interest. Such characteristics also render carbohydrate crosslinked glycoprotein crystals useful as catalytic and binding components for the production of biosensing devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>